Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
E. A. Chiocca
Brigham and Women's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Advantagene, Inc.
Payment for services (e.g., consulting fees, honoraria, paid authorship)
The research seeks (1) to address the clearance of oHSV by natural killer (NK) cells and macrophages before the virus can sufficiently replicate and result in tumor cytotoxicity, and (2) conduct a phase I clinical trial of rQNestin34.5 for recurrent GBM, and the role of immune checkpoint signaling and blockade in modulating the efficacy of oHSV immunostimulation. Advantagene is developing the GMCI platform technology used in the study, which is designed to stimulate a patient's immune system to naturally fight against his or her cancer.. Dr. Chiocca is a paid member of Advantagene’s SBA.
Circumventing barriers to effective oncolytic virotherapy of malignant gliomas
PROJECT NARRATIVE - OVERALL Glioblastoma (GBM) remains one of the deadliest cancers. We will research a type of immunotherapy that uses ?tumor-killing? viruses to directly destroy GBM and also stimulate an immune response against the tumor. Our group will perform a clinical trial of a particular tumor-killing virus we engineered, but also study how to make this even more efficacious in mouse models of GBM in order to get the body's immune system to reject the recurrence of this cancer.
Filed on September 24, 2018.
Tell us what you know about E. A. Chiocca's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “E. A. Chiocca”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| E. A. Chiocca | Massachusetts General Hospital | Conflict of Interest | Advantagene, Inc. | $20,000 - $39,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.